LUCETAM®
UkraineNo, this drug must not be used in children.
Frequently asked questions
What side effects can piracetam cause?
Nervousness, hyperkinesia (excessive movement), and weight gain may occur frequently. Depression and asthenia (weakness) occur infrequently. Isolated cases of headache, insomnia, dizziness, nausea, abdominal pain, skin rash, and other reactions are also possible.
What should be done in case of piracetam overdose?
In case of overdose, symptoms usually manifest as an intensification of side effects. There is no specific antidote; treatment is symptomatic; hemodialysis may be used to remove the drug from the body.
Can the drug be mixed with other medicines?
The drug should not be mixed with other medicinal products.
How should the drug be stored correctly?
Store at a temperature not exceeding 25 ºC in a place inaccessible to children.
Can the drug be used after the expiration date?
No, the drug must not be used after the expiration date indicated on the packaging.
Instructions for use
Children. Do not use. Overdose. Symptoms: intensification of the drug's adverse effects. Symptoms of overdose were observed with oral administration of the drug at a dose of 75 g. Treatment is symptomatic. There is no specific antidote; hemodialysis can be used (eliminates 50–60% of piracetam). Adverse reactions.
Organ system according to WHO organ classification system |
Common
|
Uncommon
|
Nervous system disorders |
Hyperkinesia |
|
Metabolism and nutrition disorders |
Weight increased |
|
Psychiatric disorders |
Irritability |
Depression |
General disorders and administration site conditions |
Asthenia |
Adverse reactions reported during post-marketing surveillance are listed below by system organ classes.
Blood and lymphatic system disorders.
Rare: haemorrhagic disorders.
Immune system disorders.
Rare: hypersensitivity, anaphylactoid reactions.
Psychiatric disorders.
Frequent: nervousness.
Uncommon: depression.
Rare: increased excitability, anxiety, confusion, hallucinations.
Nervous system disorders.
Frequent: hyperkinesia.
Uncommon: somnolence.
Rare: ataxia, loss of balance, increased frequency of epileptic seizures, headache, insomnia, tremor.
Ear and labyrinth disorders.
Rare: dizziness.
Gastrointestinal disorders.
Rare: abdominal pain, upper abdominal pain, diarrhoea, nausea, vomiting.
Skin and subcutaneous tissue disorders.
Rare: angioneurotic oedema, dermatitis, rash, urticaria, pruritus.
Reproductive system and breast disorders.
Rare: increased libido.
Vascular disorders.
Very rare: hypotension, thrombophlebitis.
General disorders and administration site conditions.
Uncommon: asthenia.
Very rare: injection site pain, chills.
Investigations.
Frequent: weight gain.
Shelf life.
3 years.
Do not use the medicinal product after the expiry date stated on the packaging.
Storage conditions.
Store at a temperature not exceeding 25 °C in a place inaccessible to children.
Incompatibilities.
Not applicable. Studies have not been conducted. The medicinal product must not be mixed with other medicinal products.
Packaging.
5 ml (1 g) in an ampoule; 5 ampoules in a blister; 2 blisters in a cardboard box.
15 ml (3 g) in an ampoule; 4 ampoules in a blister; 1 or 5 blisters in a cardboard box.
Prescription status.
Prescription only.
Manufacturer.
EGIS Pharmaceuticals PLC.
Address of the manufacturer and location of operations.
1165 Budapest, Bokenyfoldi ut. 118–120, Hungary.
Similar drugs
| Brand name | Dosage form | Active substance / Dosage | Manufacturer |
|---|---|---|---|
| PIRACETAM | solution for injection |
|
PJSC "Halychpharm" |
| PIRACETAM | solution for injection |
|
PJSC "Lekhim - Kharkiv" |
| PIRACETAM | solution for injection |
|
Farmak JSC |
| PIRACETAM-DARNITSA | solution for injection |
|
PJSC «Pharmaceutical Company «Darnitsa» |
| PIRACETAM-ZDOROVYA | solution for injection |
|
LLC "Corporation "Zdorovya" |
| TORACETAM | solution for injection |
|
Farmasel LLC |
The original data is available in the language of the country of manufacture.
Data source: State Register of Medicinal Products of Ukraine
Data last verified: August 13, 2026